ClinicalTrials.gg
CompletedNCT07429331Updated Jun 3, 2026

Drug Interaction and Food Effect Study of CS0159

A Phase 1 interventional study of CS0159 Tablet and Rifampicin Capsule in Healthy Volunteers, sponsored by Cascade Pharmaceuticals, Inc. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Purpose: This study aims to evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetic (PK) profile of CS0159 tablets and to assess the drug-drug interactions (DDI) when CS0159 is co-administered with a strong CYP3A4 inducer (rifampicin) and a strong CYP3A4 inhibitor (itraconazole), respectively.

Design:

Part A (DDI - Induction): Single-center, open-label, fixed-sequence design. Sixteen healthy participants will receive a single dose of CS0159 (4 mg) under fasting conditions on Day 1, rifampicin alone (600 mg, QD) under fasting conditions on Days 2-8, and co-administration of CS0159 with rifampicin under fasting conditions on Day 9.

Part B (Food Effect \& DDI - Inhibition): Single-center, open-label, two-phase design. Sixteen healthy participants will first undergo a randomized, two-period, two-sequence crossover food effect study (CS0159 4 mg administered under fasting vs. high-fat meal conditions). All participants will then enter the second phase, receiving itraconazole (200 mg, QD) after a meal for 5 consecutive days, followed by co-administration of CS0159 with itraconazole after a high-fat meal on the 6th day.

Endpoints: The primary endpoints are the pharmacokinetic parameters of CS0159 (C\~max, AUC\~0-t, AUC\~0-∞)and other PK parameters (Tmax,t1/2,λz,AUC_%Extrap,Tlag,CL/F,V/F). Secondary endpoints include safety (adverse events, vital signs, laboratory tests, etc.) .

Read the detailed description
  1. Study Background:

    CS0159 is a novel farnesoid X receptor agonist under development for the treatment of diseases such as nonalcoholic steatohepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Preclinical studies indicate that CS0159 is primarily metabolized by the CYP3A4 enzyme. According to relevant guidelines, it is necessary to evaluate the impact of CYP3A4 modulators (rifampicin and itraconazole) on the exposure of CS0159, as well as the effect of food on its pharmacokinetics, to guide safe clinical use.

  2. Study Design and Methods:

    Overall Design: The study consists of two independent parts (Part A and Part B), planning to enroll a total of 32 healthy adult participants (both sexes) aged 18-45.

    Part A - DDI Study with Rifampicin: A fixed-sequence design is employed. Participants, under fasting conditions, sequentially receive CS0159 monotherapy, rifampicin monotherapy (for 7 consecutive days), and then co-administration of both drugs. Intensive blood sampling is performed for PK analysis.

    Part B - Food Effect and DDI Study with Itraconazole:

    Phase 1 (Food Effect): A randomized, open-label, two-period, two-sequence crossover design is used. Participants are randomly divided into two groups to receive a single dose of CS0159 under fasting and high-fat meal conditions, respectively, with a 2-day washout period between the two periods.

    Phase 2 (DDI Study with Itraconazole): All participants who complete Phase 1 enter this phase. Participants first receive itraconazole after a meal for 5 consecutive days, followed by co-administration of CS0159 with itraconazole after a high-fat meal.

    Pharmacokinetic and Safety Assessments: Blood samples are collected at scheduled time points during all CS0159 dosing periods (monotherapy or co-administration). CS0159 plasma concentrations are determined using a validated LC-MS/MS method. Throughout the study, adverse events, vital signs, physical examinations, 12-lead ECGs, and laboratory test results are continuously monitored and recorded.

  3. Statistical Methods:

Pharmacokinetic parameters will be calculated using non-compartmental analysis. For DDI analysis, analysis of variance will be performed on log-transformed C\~max\~ and AUC values, and geometric mean ratios with their 90% confidence intervals will be calculated. Food effect analysis will employ a crossover design analysis of variance. Safety data will be summarized using descriptive statistics.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Cascade Pharmaceuticals, Inc is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female participants aged between 18 and 45 years (inclusive);
  2. Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg; (BMI) within the range of 19.0 to 26.0 kg/m² (including the threshold values);
  3. Normal renal function ( calculated using the CKD-EPI equation ≥ 90 mL/min/1.73 m²);
  4. Participants (including male participants) agree to have no plans for conception from screening until 3 months after the last dose, voluntarily adopt effective measures, and have no plans for sperm or egg donation;
  5. Participants fully understand the study purpose, nature, procedures, and potential adverse events, voluntarily agree to participate as subjects, can communicate well with the investigator, comply with all study requirements, and sign the form before the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic diseases (e.g., asthma, urticaria, eczema, etc.), allergic constitution (e.g., allergy to two or more drugs), or known to CS0159, rifampicin, itraconazole, or any ;
  2. Participants with findings, as judged by the investigator, of the following diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular/cerebrovascular diseases) that may complicate protocol implementation or interpretation of study results, or whom the investigator considers to be at risk from participating in the study;
  3. History of susceptibility to pruritus, or presence of conditions such as eczema/atopic dermatitis, neurodermatitis, psoriasis, or other diseases that may cause pruritus;
  4. History of interval (QTc) prolongation at screening:

    1. QTc interval prolongation on 12-lead (ECG) (QTcF ≥450 ms in males; QTcF ≥470 ms in females);
    2. Family history of hypocalcemia or long QT syndrome.
  5. History of acute or chronic bronchospasm (including treated or untreated asthma, );
  6. Occurrence of an acute illness within 2 weeks prior to the first dose;
  7. Presence of any known disease or condition that may interfere with drug absorption, distribution, metabolism, or excretion, including bile salt metabolism in the large intestine. Examples include inflammatory bowel disease, gastrectomy, cholecystectomy, etc.;
  8. Use of drugs affecting hepatic metabolic enzyme function (e.g., barbiturates, carbamazepine, phenytoin, , omeprazole, SSRIs, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to the first dose, or requirement for concomitant use of other drugs that may affect the absorption, distribution, metabolism, or excretion of the drug during the study period;
  9. History of blood donation within 3 months prior to the first dose, total blood loss ≥400 mL due to donation or other reasons within 6 months, or plans to donate blood during the study or within 3 months after study completion;
  10. Current smokers, or participants unwilling to discontinue nicotine product use from 3 months before screening and during the study, or with positive urine cotinine test results;
  11. Excessive consumption of tea, coffee, or caffeinated beverages (more than 8 cups per day, 1 cup = 250 mL) within 6 months prior to screening; or consumption of any food or beverage rich in caffeine and/or xanthine (e.g., coffee, strong tea, chocolate, caffeinated carbonated beverages, cola, etc.) from 48 hours before the first dose until the end of the study; or unwillingness to abstain from alcohol, fruit juice beverages, strenuous exercise, or other factors that may affect drug absorption, distribution, metabolism, or excretion;
  12. Average weekly alcohol consumption exceeding 14 units (1 unit = 360 mL beer, 45 mL of 40% alcohol liquor, or 150 mL wine) in the past year, or inability to abstain from alcohol during the study, or alcohol breath test result >0.0 mg/100 mL;
  13. Drug abusers or participants with positive results on drug abuse screening (morphine, tetrahydrocannabinol acid, methamphetamine, methylenedioxymethamphetamine, ketamine, and cocaine);
  14. Participation in another drug clinical trial within 3 months prior to this study (Note: The end date is defined as the date of discontinuation from the most recent clinical trial involving drugs or devices);
  15. Positive screening results for virus antibody, surface antigen, antibody, or syphilis treponemal antibody; abnormal liver function: , ALT, ALP, GGT, and TBil > (ULN);
  16. Abnormal and clinically significant findings on physical examination, vital signs, laboratory tests, 12-lead ECG, or abdominal ultrasound at screening, as judged by the investigator;
  17. Use of prescription or over-the-counter medications within 14 days prior to the first dose or within at least 5 half-lives (whichever is longer);
  18. Use of any drugs or substances (e.g., herbal medicines, grapefruit, etc.) that may affect activity within 14 days before taking the study drug and during the study period;
  19. Difficulty swallowing, intolerance to venipuncture/indwelling needles, difficulty with blood sampling, history of needle or blood phobia, special dietary requirements, or inability to comply with standardized meals;
  20. Any other conditions deemed unsuitable for participation by the investigator.

    Additional exclusion criteria for female participants:

  21. Use of oral within 30 days prior to screening until randomization;
  22. Use of long-acting estrogen or progestin injections (including progestin-containing intrauterine devices) or implants within 6 months prior to screening until randomization;
  23. Unprotected sexual intercourse with a partner within 14 days prior to screening until randomization;
  24. Positive pregnancy test;
  25. Pregnant or breastfeeding females.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part A: CS0159 + Rifampicin (DDI)

    Healthy participants receive a single oral dose of CS0159 (4 mg) under fasting conditions on Day 1, followed by oral rifampicin (600 mg) once daily under fasting conditions on Days 2-8, and then co-administration of both drugs under fasting conditions on Day 9.

    Drug: CS0159 Tablet · Drug: Rifampicin Capsule

  • Experimental
    Part B: CS0159 (Food Effect)

    The 16 enrolled participants are randomly assigned to two groups (fasting-fed group and fed-fasting group) in Phase 1, with an equal number in each group. Each group receives a single 4 mg dose per period, with a 2-day washout period (in-house).

    Drug: CS0159 Tablet

  • Experimental
    Part B: CS0159 + Itraconazole (DDI)

    Healthy participants receive oral itraconazole capsules (200 mg, two capsules of 0.1 g each) once daily in the morning under fed conditions (following a standard meal) from Day 4 to Day 8 (D4\~D8), which corresponds to days 2 to 6 after completing the second period of Phase 1. This constitutes 5 consecutive days of itraconazole administration. On the 6th administration day (D9), participants simultaneously take itraconazole capsules (200 mg) and CS0159 tablets (4 mg, two tablets of 2 mg each) under fed conditions (following a high-fat meal).

    Drug: CS0159 Tablet · Drug: Itraconazole Capsule

Interventions

  • DrugLinafexorStudies of LinafexorLinafexor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A novel, selective farnesoid X receptor (FXR) agonist.

    Also known as: Investigational drug (FXR agonist)

  • DrugRifampinStudies of RifampinRifampin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A strong cytochrome P450 3A4 (CYP3A4) enzyme inducer.

    Also known as: CYP3A4 inducer (perpetrator drug)

  • DrugItraconazoleStudies of ItraconazoleItraconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A strong cytochrome P450 3A4 (CYP3A4) enzyme inhibitor.

    Also known as: CYP3A4 inhibitor (perpetrator drug)

06

What researchers measure

Primary outcomes

  1. Cmax of CS0159

    Maximum observed plasma concentration (Cmax) of CS0159

    Time frame: Day 1, Day 3, Day 9

  2. AUC0-t of CS0159

    Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of CS0159

    Time frame: Day 1, Day 3, Day 9

  3. AUC0-∞ of CS0159

    Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of CS0159

    Time frame: Day 1, Day 3, Day 9

  4. Tmax of CS0159

    Time to reach Cmax (Tmax)

    Time frame: Day 1, Day 3, Day 9

  5. t1/2 of CS0159

    terminal elimination half-life (t1/2)

    Time frame: Day 1, Day 3, Day 9

  6. CL/F of CS0159

    apparent oral clearance (CL/F)

    Time frame: Day 1, Day 3, Day 9

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Observe all adverse medical events occurring in participants during the clinical study period, including clinical symptoms and clinically significant abnormalities in vital signs, physical examinations, laboratory tests, and electrocardiograms. Record their clinical manifestations, severity, time of onset, time of resolution, duration, management measures, outcomes, and assess their relationship to the investigational product.

    Time frame: From screening until 7 days after the last dose.

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Mar 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 24, 2026
StartActual
Mar 9, 2026
Primary completionActual
Mar 25, 2026
CompletionActual
Apr 1, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07429331
Lead sponsor
Cascade Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 9, 2026
Primary completion
Mar 25, 2026
Completion
Apr 1, 2026
Last update
Jun 3, 2026

Study contacts

Yun Liu
principal investigator · Shanghai Xuhui District Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linafexor

Start the discussion